KE
Therapeutic Areas
Larimar Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Nomlabofusp (CTI-1601) | Friedreich's Ataxia | Phase 2 |
Leadership Team at Larimar Therapeutics
CB
Carole Ben-Maimon
President and Chief Executive Officer
GS
Gopi Shankar
Chief Development Officer
RC
Rusty Clayton
Chief Medical Officer
MC
Michael Celano
Chief Financial Officer
JB
John Berman
Vice President of Finance and Administration
JJ
Jennifer Johansson
Vice President, Legal and Compliance
NS
Noreen Scherer
Vice President of Clinical Operations
FM
Francis Michael Conway
Vice President and Controller
MH
Mohamed Hamdani
Vice President, Statistics and Quantitative Sciences
AC
Adrienne Clements-Egan
Vice President, Bioanalytics and Developability